Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Chronic Myeloproliferative Neoplasias

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

Leukemia volume 23, pages 900–904 (2009)Cite this article

Abstract

TET2 (TET oncogene family member 2) is a candidate tumor suppressor gene located at chromosome 4q24, and was recently reported to be mutated in ∼14% of patients with JAK2V617F-positive myeloproliferative neoplasms. We used high-throughput DNA sequence analysis to screen for TET2 mutations in bone marrow-derived DNA from 48 patients with systemic mastocytosis (SM), including 42 who met the 2008 WHO (World Health Organization) diagnostic criteria for SM and 6 with FIP1L1-PDGFRA. Twelve (29%) SM, but no FIP1L1-PDGFRA patients, had TET2 mutations. A total of 17 mutations (13 frameshift, 2 nonsense and 2 missense) were documented in 2 (15%) of 13 indolent SM patients, 2 (40%) of 5 aggressive SM, and 8 (35%) of 23 SM associated with a clonal non-mast cell-lineage hematopoietic disease (P=0.52). KITD816V was detected by PCR sequencing in 50 or 20% of patients with or without TET2 mutation (P=0.05), respectively. Multivariable analysis showed a significant association between the presence of TET2 mutation and monocytosis (P=0.0003) or female sex (P=0.05). The association with monocytosis was also observed in non-indolent SM (n=29), in which the presence of mutant TET2 did not affect survival (P=0.98). We conclude that TET2 mutations are frequent in SM, segregate with KITD816V and influence phenotype without necessarily altering prognosis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Delhommeau F, Dupont S, James C, Masse A, le Couedic JP, Valle VD et al. TET2 is a novel tumor suppressor gene inactivated in myeloproliferative neoplasms: identification of a Pre-JAK2 V617F event. ASH Annual Meeting Abstracts 2008; 112: lba-3: Late-Breaking Abstract.

    Google Scholar 

  2. Viguie F, Aboura A, Bouscary D, Ramond S, Delmer A, Tachdjian G et al. Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement? Leukemia 2005; 19: 1411–1415.

    Article  CAS  Google Scholar 

  3. Tefferi A, Vardiman JW . Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14–22.

    Article  CAS  Google Scholar 

  4. Jaffe ES, Harris NL, Stein H, Vardiman JW . World Health Organization Classification of Tumours of Hematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001, pp 1–351.

    Google Scholar 

  5. Dewald GW, Broderick DJ, Tom WW, Hagstrom JE, Pierre RV . The efficacy of direct, 24-h culture, and mitotic synchronization methods for cytogenetic analysis of bone marrow in neoplastic hematologic disorders. Cancer Genet Cytogenet 1985; 18: 1–10.

    Article  CAS  Google Scholar 

  6. Pardanani A, Reeder TL, Kimlinger TK, Baek JY, Li CY, Butterfield JH et al. Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leuk Res 2003; 27: 739–742.

    Article  CAS  Google Scholar 

  7. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008; 22: 756–761.

    Article  CAS  Google Scholar 

  8. Afonja O, Amorosi E, Ashman L, Takeshita K . Multilineage involvement and erythropoietin-‘independent’ erythroid progenitor cells in a patient with systemic mastocytosis. Ann Hematol 1998; 77: 183–186.

    Article  CAS  Google Scholar 

  9. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both ‘atypical’ myeloproliferative disorders and myelodysplastic syndromes. Blood 2005; 106: 1207–1209.

    Article  CAS  Google Scholar 

  10. Sotlar K, Bache A, Stellmacher F, Bultmann B, Valent P, Horny HP . Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a (corrected) clonal hematological non-mast (corrected) cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F. J Mol Diagn 2008; 10: 58–66.

    Article  CAS  Google Scholar 

  11. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108: 2366–2372.

    Article  CAS  Google Scholar 

  12. Mayerhofer M, Gleixner KV, Hoelbl A, Florian S, Hoermann G, Aichberger KJ et al. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol 2008; 180: 5466–5476.

    Article  CAS  Google Scholar 

  13. Verstovsek S, Tefferi A, Cortes J, O’Brien S, Garcia-Manero G, Pardanani A et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008; 14: 3906–3915.

    Article  CAS  Google Scholar 

  14. Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005; 106: 2865–2870.

    Article  CAS  Google Scholar 

  15. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603–625.

    Article  CAS  Google Scholar 

  16. Kahler C, Didlaukat S, Feller AC, Merz H . Sensitive and reliable detection of Kit point mutation Asp 816 to Val in pathological material. Diagn Pathol 2007; 2: 37.

    Article  Google Scholar 

  17. Mertens F, Johansson B, Mitelman F . Age- and gender-related heterogeneity of cancer chromosome aberrations. Cancer Genet Cytogenet 1993; 70: 6–11.

    Article  CAS  Google Scholar 

  18. Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131: 208–213.

    Article  CAS  Google Scholar 

  19. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY et al. The JAK2 tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 2005; 131: 320–328.

    Article  CAS  Google Scholar 

  20. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201–1214.

    Article  CAS  Google Scholar 

  21. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004; 104: 3038–3045.

    Article  CAS  Google Scholar 

  22. Gotlib J, Cools J . Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008; 22: 1999–2010.

    Article  CAS  Google Scholar 

  23. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162–2168.

    Article  CAS  Google Scholar 

  24. Deguchi K, Gilliland DG . Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML. Leukemia 2002; 16: 740–744.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Adriana Heguay and Igor Dolgalev from the Memorial Sloan-Kettering Cancer Center, New York, NY, USA are acknowledged for their assistance with sequence analysis. The current study was supported in part by grants from the Myeloproliferative Disorders Foundation, Chicago, IL, USA.

Author information

Authors and Affiliations

  1. Divisions of Hematology and Hematopathology, Departments of Medicine and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA

    A Tefferi, K-H Lim, T L Lasho, C M Finke, C-Y Li & A Pardanani

  2. Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    R L Levine, O Abdel-Wahab & J Patel

  3. Department of Medicine, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    R L Levine & O Abdel-Wahab

  4. Division of Hematology-Oncology, Mackay Memorial Hospital and Mackay Medicine, Nursing and Management College, Taipei, Taiwan

    K-H Lim

  5. Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    A Mullally & D G Gilliland

  6. Howard Hughes Medical Institute, Boston, MA, USA

    D G Gilliland

Authors
  1. A Tefferi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R L Levine
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K-H Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. O Abdel-Wahab
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T L Lasho
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C M Finke
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Mullally
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C-Y Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Pardanani
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. D G Gilliland
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Tefferi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tefferi, A., Levine, R., Lim, KH. et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 23, 900–904 (2009). https://doi.org/10.1038/leu.2009.37

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2009.37

Keywords

This article is cited by

Search

Advanced search

Quick links